Kassubek, Jan http://orcid.org/0000-0002-7106-9270
Factor, Stewart A. http://orcid.org/0000-0002-0449-973X
Balaguer, Ernest http://orcid.org/0000-0001-9258-1735
Schwarz, Johannes http://orcid.org/0009-0002-8314-5573
Chaudhuri, K. Ray http://orcid.org/0000-0003-2815-0505
Isaacson, Stuart H. http://orcid.org/0000-0002-9914-5706
Wu, Stacy
Denecke Muhr, Carmen
Kulisevsky, Jaime http://orcid.org/0000-0003-4870-1431
Funding for this research was provided by:
Sunovion
Bial – Portela & C
Universitätsklinikum Ulm
Article History
Received: 3 January 2024
Revised: 5 March 2024
Accepted: 10 March 2024
First Online: 28 March 2024
Declarations
:
: Jan Kassubek has received honoraria or consultation fees from AbbVie, Bial, Biogen, Desitin, Esteve, Licher MT, Medtronic, NeuroDerm, Novartis, STADA, UCB Pharma, and Zambon; in addition, he is Specialty Chief Editor for <i>Frontiers in Neurology</i> (section Applied Neuroimaging) and Associate Editor (Neurology) for <i>Therapeutic Advances in Chronic Disease</i>. Stewart A. Factor has received honoraria from Lundbeck, Biogen, and Takeda; grants from Medtronic, Boston Scientific, Sun Pharmaceuticals Advanced Research Company, Aspen, Biohaven, Neurocrine, Voyager, Prilenia Therapeutics, CHDI Foundation, Michael J. Fox Foundation, NIH 1 P50 NS123103-01, NIH 1R01NS125294-01, and Parkinson Foundation; royalties from Demos, Blackwell Futura, Springer for textbooks, and UpToDate; and other support from Cronos. Ernest Balaguer is Director of Research at Hospital Universitari General de Catalunya and signs agreements with the hospital to perform clinical trials. Johannes Schwarz received honoraria in the past 5 years from UCB, BIAL and AbbVie for presentations and consulting. K. Ray Chaudhuri has received funding from Parkinson’s UK, NIHR, UCB, and the European Union; he received honoraria from UCB, Abbott, Britannia, US Worldmeds, and Otsuka Pharmaceuticals; and acted as a consultant for AbbVie, UCB, and Britannia. Stuart H. Isaacson reports honoraria for CME, consultancy, research grants, and/or promotional speaker work on behalf of AbbVie, Acadia Pharmaceuticals Inc., Acorda Therapeutics Inc., Adamas Pharmaceuticals Inc., Addex Therapeutics, AFFiRiS AG, Alexza Pharmaceuticals, Allergan, Amarantus BioScience, Amneal Pharmaceuticals, Aptinyx, Axial Therapeutics Inc., Axovant Gene Therapies, BenevolentAI, Biogen, Britannia Pharmaceuticals, Cadent Therapeutics, Cala Health, Cerecor Inc., Cerevel Therapeutics, Cipla, Eli Lilly, Enterin Inc., GE HealthCare, Global Kinetics Pty Ltd., Impax Laboratories, Impel NeuroPharma, Intec Pharma, Ipsen, Jazz Pharmaceuticals, Kyowa Kirin, Lundbeck, Merz Pharmaceuticals, Michael J. Fox Foundation, Mitsubishi Tanabe Pharma, Neuraly, Neurocrine Biosciences, NeuroDerm, Parkinson Study Group, Pharma Two B, Prilenia Therapeutics, Promentis Pharmaceuticals Inc., Revance, Roche, Sanofi, Sunovion Pharmaceuticals Inc., Sun Pharma, Supernus Pharmaceuticals Inc., Teva Pharmaceuticals, Theravance Biopharma, and UCB. Stacy Wu is an employee of Sumitomo Pharma America Inc. Carmen Denecke Muhr is an employee of Bial-Portela & Cª. Jaime Kulisevsky has received consulting fees from Roche and Zambon; honoraria from Zambon, Teva, Bial, UCB; research funding from Roche, Zambon, Ciberned; Instituto de Salud Carlos III; Fundació La Marató de TV3.
: The study was conducted in accordance with International Council for Harmonisation (ICH) Good Clinical Practice Guidance, the ethical principles that had their origin in the Declaration of Helsinki, and all applicable local law(s) and regulation(s). In accordance with ICH guidance, the protocol (including the final version of the patient informed consent form) was approved by the Institutional Review Board (IRB)/Independent Ethics Committee (IEC) before any patients were enrolled (see Supplementary Information for details of central IRBs/IECs).
: All patients provided written informed consent prior to participation in the study.